Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

Laurent Phely; Luca Hensen; Christoph Faul; Christer Alexander Ruff; Dina Schneider; Wolfgang Andreas Bethge; Claudia Lengerke

doi:10.1001/jamaoncol.2024.0473

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

JAMA Oncol. 2024 Jun 1;10(6):821-824. doi: 10.1001/jamaoncol.2024.0473.

Authors

Laurent Phely¹, Luca Hensen¹, Christoph Faul¹, Christer Alexander Ruff², Dina Schneider³, Wolfgang Andreas Bethge¹, Claudia Lengerke¹

Affiliations

¹ Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany.
² Department of Diagnostic and Interventional Neuroradiology, University Hospital Tubingen, Tubingen, Germany.
³ Miltenyi Biotec, Gaithersburg, Maryland.

No abstract available

Plain language summary

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.

Publication types

Case Reports

MeSH terms

Adult
Antigens, CD19* / immunology
Female
Humans
Immunotherapy, Adoptive* / methods
Male
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / immunology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Receptors, Chimeric Antigen / immunology
Sialic Acid Binding Ig-like Lectin 2* / immunology
Transplantation, Homologous

Substances

Antigens, CD19
Sialic Acid Binding Ig-like Lectin 2
CD22 protein, human
Receptors, Chimeric Antigen
CD19 molecule, human